Science at the Edge: Psychedelics and Mental Health
With new laws and shifting public perceptions, Colorado is at the forefront of the conversation about the potential of psychedelics to transform mental health care. While science suggests its effectiveness in treating mental health disorders and providing relief and benefits for palliative care, there is still much to learn about these drugs, their uses, benefits, and side effects. This installment of the Science at the Edge series will explore the growing field of research and evolving medical landscape around these drugs.
The webinar features Dr. Scott Thompson, Director of the Center for Novel Therapeutics at the University of Colorado School of Medicine’s Department of Psychiatry, in conversation with Max Neumeyer, Deputy Director of Policy and Engagement at The Institute of Science & Policy. Dr. Thompson unpacks the promise and limitations of these emerging therapies, discusses how the research is moving beyond anecdotes towards more rigorous evidence, and considers the complex questions still ahead.
Learn more about the Institute at institute.dmns.org.